-->

Tag: Jemperli

Home / Jemperli

Categories

Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer

Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progr...
jemperli

Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or a...
jemperli

Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or ...
jemperli

Scan the code